Health expenditure worldwide will continue to grow. People are living to an increasingly advanced age thanks to improved medical care, with the proportion of the ageing population thereby steadily increasing. In addition, lifestyle and old age diseases – mostly chronic diseases – are playing an increasing role, many of them also due to lifestyle changes. The sharp increase in the occurrence of sun-induced non-melanoma skin cancer, as well as the associated medical treatment and prophylaxis are consequences of this. 

With PDT, the company considers itself to be excellently positioned. As a biopharmaceutical company, Biofrontera specializes in the development and commercialization of dermatological drugs. Biofrontera has been marketing PDT and its flagship drug for the treatment of non-melanoma skin cancer and its precursors in the EU since 2012 and in the USA since 2016. 

The company intends to expand its label for further dermatological indications in the future. 

NEXT ->